Dongguan, China

Jianchao Deng

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Sunshine Lake Pharma Co., Ltd.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Jianchao Deng

Introduction

Jianchao Deng is a prominent inventor based in Dongguan, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target thyroid hormone receptors. His work is crucial for advancing treatments for various diseases.

Latest Patents

Jianchao Deng holds a patent for a chemical compound as a thyroid hormone beta receptor agonist and its use. This patent describes a pharmaceutical composition that includes the chemical compound, which can be utilized in the preparation of drugs aimed at preventing, treating, or mitigating diseases mediated by the agonistic thyroid hormone β receptor. Notably, this compound is particularly relevant for developing drugs to treat non-alcoholic fatty liver diseases. He has 1 patent to his name.

Career Highlights

Deng is associated with Sunshine Lake Pharma Co., Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His expertise in chemical compounds and their applications in medicine has positioned him as a valuable asset in his field.

Collaborations

Throughout his career, Jianchao Deng has collaborated with notable colleagues, including Zheng Gu and Jianhao Li. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Jianchao Deng's work in developing thyroid hormone receptor agonists represents a significant advancement in pharmaceutical innovation. His contributions are vital for the ongoing research and treatment of various health conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…